Triazine angiogenesis inhibitors

Details Triazine angiogenesis inhibitors Triazine angiogenesis inhibitors

1998-12-10

2000-11-21

Shah, Mukund J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

544206, 544207, A61K 3153, A61P 3504, A61P 910, C07D25170

Patent

active

061503622

ABSTRACT:
Compounds having Formula I ##STR1## or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting anglogenesis in a mammal.

REFERENCES:
patent: 2532519 (1950-12-01), Simons et al.
patent: 2535968 (1950-12-01), Thurston et al.
patent: 2937170 (1960-05-01), Shapiro
patent: 3379661 (1968-04-01), Gynn et al.
patent: 3478026 (1969-11-01), Enkoji et al.
patent: 3729468 (1973-04-01), Tani et al.
patent: 3740399 (1973-06-01), Murai et al.
patent: 4389333 (1983-06-01), Werle et al.
patent: 4501689 (1985-02-01), Yanagawa
patent: 4554275 (1985-11-01), Sempuku et al.
patent: 5371218 (1994-12-01), Cipolli et al.
Borkovec et al. Triazinyl J. Econ. Entomol. 65(1), 69-73, CA Abstract provided. CA 76:122932, 1972.
Bicking et al. Pyrazine Diuretics. J. Med. Chem. 8, 638-642, 1965.
Sheinkman et al. Vopr. Khim. Khim. Tekinol. 51, 62-66. CAPLUS Abstract provided. CA 90:2044044, 1978.
Case et al. J. Heterocycl. Chem. 4(4), 483-5. CAPLUS Abstract provided. CA 68: 39539, 1967.
Chapleo et al. J. Med. Chem. 26(6) 823-31. CAPLUS Abstract provided. CA 99: 22392, 1983.
Case et al. J. Amer. Chem. Soc. 91, 905 -906, 1958.
Vanderhock et al. J. Med. Chem. 16, 1305-1306, 1973.
Case et al J. Org. Chem. 31, 2398-2400, 1966.
Mackenzie et al. J. Chem. Soc. Perkin. Trans. 1 (3) 295-298, 1972.
Stevens et al. Eur. J. Med. Chim. Ther. 375-9. CAPLUS abstract provided. CA 102: 62195, 1985.
Y. Sato et al., FEBS LETTERS, vol. 322, No. 2, pp. 155-158 (1993).
T. Hosokawa et al., Oncology Reports, vol. 1, pp. 93-95 (1994).
M. Ono et al., Cancer Research, vol. 56, pp. 1512-1516 (1996).
Hori, et al., "Triazine Derivatives Inhibit rat hepatocarcinogenesis but do not enhance gap junctional intercellular communication", Jpn. J. Cancer Res., vol. 88, Jan. 1997, pp. 12-17.
Vanderhoek, et al., "Bis(dimethylamine)-s-triazinyl antiinflammatory agents", Journal of Medicinal Chemistry, vol. 16, No. 11, pp. 1305-1306.
Sato, et al., "Irsogladine is a potent inhibitor of angiogensis", Chemical Abstracts, Colombus, OH, vol. 119, No. 3, p. 56.

Affiliated with

Also associated with

Rating

Triazine angiogenesis inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Triazine angiogenesis inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazine angiogenesis inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1257410